All Good Things... | GenomeWeb

All Good Things...

Despite its well-received genome-wide association scan papers, DeCode Genetics is on the brink of extinction, says Technology Review. According to the article, DeCode has spent more than $600 million, never made a profit, and has $3.7 million left as its stock hovers at 57 cents, down from $29 when the company first launched. Founder Kari Stefansson recently told investors that he is re-envisioning DeCode as a gene-based diagnostics company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.